Tocolytics: Nifedipine, Atosiban, Indomethacin, Beta-Agonists & Magnesium Sulfate

Learning objectives

• Identify when short-term tocolysis can improve neonatal preparation and when delaying delivery is dangerous.
• Compare nifedipine, atosiban, indomethacin, beta-agonists, nitric-oxide donors and magnesium sulfate.
• Calculate practical regimens while monitoring maternal blood pressure, pulse, fluid balance and fetal wellbeing.
• Recognise contraindications: infection, severe pre-eclampsia/eclampsia, bleeding, fetal compromise, demise or lethal anomaly.
• Manage pulmonary oedema, hypotension, beta-agonist toxicity, magnesium toxicity and NSAID fetal effects.

1. What tocolysis can and cannot do

Preterm labour is regular painful uterine activity with cervical change before 37+0 weeks. Tocolysis may suppress contractions but generally does not reverse cervical pathology, infection, placental abruption or membrane rupture. The benefit is greatest when delaying birth allows corticosteroids to mature the fetal lungs, transfer to a neonatal unit or magnesium sulfate for neuroprotection. Maintenance or prophylactic tocolysis after an initial course has limited evidence and should not become routine.

NICE guidance offers/considers nifedipine for selected women from about 24+0 to 33+6 weeks, with gestational limits and local protocols varying. The decision is specialist and off-label in some jurisdictions.

2. Classification and mechanisms

3. Nifedipine

Mechanism and indications

Nifedipine relaxes myometrial smooth muscle by inhibiting L-type calcium influx. It is often preferred because it is oral, rapidly acting and has fewer maternal adverse effects than beta-mimetics. It is used to delay threatened spontaneous preterm birth long enough for corticosteroids/transfer when maternal and fetal status are stable.

Example oral regimens

• One protocol: 20 mg orally initially; repeat 20 mg after 30 minutes if contractions persist, then 20 mg every 3–8 hours for up to 48 hours.
• Another: 10 mg orally every 20 minutes for up to four doses during the loading period, then 20 mg every 4–6 hours. Some guidelines use a 30 mg loading dose followed by 10–20 mg every 4–6 hours.
• Do not exceed the local protocol maximum (often 120–180 mg/day). Stop or reduce for symptomatic hypotension, severe tachycardia or maternal deterioration.

Contraindications and adverse effects

• Hypotension, shock, significant cardiac disease, severe aortic stenosis, allergy or severe hepatic impairment.
• Do not combine casually with beta-mimetics, magnesium sulfate or nitrates because hypotension and cardiovascular toxicity may be additive; if combination is unavoidable in a specialist unit, use intensive monitoring.
• Common: flushing, headache, dizziness, nausea, palpitations and tachycardia.
• Emergency: profound hypotension, myocardial ischaemia, pulmonary oedema or syncope—stop the drug, lie the patient laterally, assess ABCs, give cautious fluids and obtain obstetric/critical-care help.

4. Atosiban

Atosiban is a competitive oxytocin/vasopressin V1a receptor antagonist. By reducing oxytocin-mediated calcium signalling it decreases contraction frequency and tone, with little direct effect on maternal blood pressure.

Use only the licensed product protocol because concentrations and infusion preparation vary. Nausea, headache, dizziness, flushing and injection-site reactions are common. Avoid in gestational age below the licensed range, significant haemorrhage, placental abruption, severe pre-eclampsia/eclampsia, fetal compromise or intrauterine infection.

5. Indomethacin and other prostaglandin-synthesis inhibitors

Indomethacin inhibits COX-1/COX-2 and reduces prostaglandins that promote cervical ripening and uterine contractions. It can be useful for short courses at earlier gestations but fetal toxicity increases with advancing gestation.

• Example regimen: 50–100 mg orally as a loading dose, optionally repeated after one hour, then 25–50 mg every 6 hours. Limit treatment to the shortest possible course, often no more than 48 hours.
• Gestational limit: avoid at or beyond about 32 weeks because of premature ductus arteriosus constriction/closure and oligohydramnios. Confirm local protocol.
• Contraindications: NSAID allergy/asthma, peptic ulcer or GI bleeding, renal disease, thrombocytopenia, significant bleeding, fetal ductal abnormality or oligohydramnios.
• Monitoring: maternal renal function/GI symptoms and ultrasound assessment of amniotic fluid/ductus if therapy is prolonged or repeated.

6. Beta-adrenergic agonists

Ritodrine, terbutaline, salbutamol and isoxsuprine increase cAMP and reduce myometrial calcium. The supplied teaching deck describes ritodrine 50 micrograms/minute IV, increased every 10 minutes until contractions are suppressed or fetal heart rate response is concerning; older protocols also used 10 mg IM every 4–6 hours followed by oral therapy. Prolonged use beyond 48 hours is not recommended.

Avoid beta-mimetics in maternal cardiac disease, tachyarrhythmia, severe hypertension, hyperthyroidism, poorly controlled diabetes, pulmonary hypertension or significant placental bleeding. In contemporary practice they are generally not first-line.

7. Magnesium sulfate: neuroprotection, not routine tocolysis

Magnesium sulfate is used for fetal neuroprotection when very preterm birth is imminent and for prevention/treatment of eclamptic seizures. It may reduce neuromuscular excitability but does not reliably prolong pregnancy and should not be selected as routine tocolysis.

• Neuroprotection example: 4–6 g IV loading dose over 15–30 minutes, followed by 1–2 g/hour for up to 12–24 hours or until birth, according to local protocol.
• Baseline checks: respiratory rate, patellar reflexes, urine output, serum creatinine and cardiovascular status.
• Toxicity: flushing, nausea, headache, drowsiness, blurred vision, loss of reflexes, respiratory depression, hypotension, bradycardia and cardiac arrest.
• Antidote: stop infusion, support airway/breathing and give calcium gluconate 1 g IV slowly for life-threatening toxicity, with renal/critical-care support.
• Interaction: do not combine routinely with nifedipine because hypotension and neuromuscular effects may be additive.

8. Nitric-oxide donors

Nitroglycerin releases nitric oxide, increasing cGMP and relaxing smooth muscle. Transdermal or sublingual use has been described as rescue uterine relaxation, but headache, flushing and hypotension limit use. Avoid with phosphodiesterase-5 inhibitors, severe hypotension, shock or raised intracranial pressure. It is not a standard first-line tocolytic.

9. Indications and contraindications

Potential indication

• Suspected or diagnosed spontaneous preterm labour, usually when gestational age is within the local neonatal-benefit window and membranes are intact or the protocol supports treatment.
• To gain up to 48 hours for antenatal corticosteroids, fetal neuroprotection or maternal transfer.
• Selected threatened abortion/dysmenorrhoea uses are historical or context-specific and should not distract from diagnosis of bleeding, ectopic pregnancy, abruption or infection.

Do not tocolyse when

• Intrauterine infection/chorioamnionitis or maternal sepsis.
• Severe pre-eclampsia/eclampsia, uncontrolled maternal haemorrhage or placental abruption.
• Non-reassuring fetal status, fetal demise or lethal congenital/chromosomal anomaly.
• Advanced labour where delay will not achieve a meaningful neonatal benefit, or ruptured membranes with a contraindicating infection/bleeding context.
• Serious maternal contraindication to the chosen drug—hypotension for nifedipine, significant liver/renal/GI disease for indomethacin, or cardiac/metabolic disease for beta-agonists.

10. Monitoring while giving a tocolytic

• Maternal BP, heart rate, respiratory rate, oxygen saturation, temperature, pain and fluid balance.
• Continuous or regular fetal heart-rate assessment and contraction frequency; reassess cervical change.
• Urine output, lung examination and oxygen requirement—especially with beta-agonists, magnesium or large IV-fluid loads.
• Glucose and potassium with beta-agonists; creatinine and reflexes with magnesium; renal/GI symptoms with indomethacin.
• Stop at 48 hours or earlier when the corticosteroid/transfer window is complete, contractions stop, serious adverse effects occur or delivery is safer.

11. Clinical cases

12. High-yield points

• Tocolysis buys time; it does not cure preterm labour.
• Nifedipine is a common first-line agent; monitor BP and avoid severe hypotension.
• Atosiban blocks oxytocin receptors and is an IV specialist alternative.
• Indomethacin is a short-course early-preterm option; avoid at or beyond about 32 weeks because of ductal and amniotic-fluid effects.
• Beta-agonists cause tachycardia, hypokalaemia, hyperglycaemia and pulmonary oedema and are rarely first-line now.
• Magnesium sulfate is primarily for eclampsia treatment/prevention and fetal neuroprotection, not routine tocolysis.
• Never delay delivery for chorioamnionitis, abruption, severe pre-eclampsia/eclampsia, fetal compromise or fetal demise.

13. Sources and further reading

• Supplied SlideShare: A presentation on tocolytics usage in OBG.
• NICE: Preterm labour and birth recommendations.
• WHO updated recommendations on preterm birth.
• ACOG teaching resource: contraindications to tocolysis.